Bone Marrow Aspirate ConcentrateIs Equivalent to Platelet-Rich Plasma for theTreatment of Knee Osteoarthritis at 1 Year
Background: Approximately 47 million people in the United States have been diagnosed with arthritis. Autologous platelet-richplasma (PRP) injections have been documented to alleviate symptoms related to knee osteoarthritis (OA) in randomized controlledtrials, systematic reviews, and meta-analyses. Autologous bone marrow aspirate concentrate (BMC) injections have also emergedas a treatment option for knee OA, with a limited clinical evidence base.